ANEB - NASDAQ
Anebulo Pharmaceuticals, Inc.
$1.72
-33%Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
At a Glance
Live Snapshotaneb
EPS
Last Annual Value
-0.25
3-Year CAGR
5%
5-Year CAGR
-102%
10-Year CAGR
-42%
Anebulo Pharmaceuticals, Inc. Competitors Analysis of EPS
| Company | EPS | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Anebulo Pharmaceuticals, Inc. NASDAQ:ANEB | -0.25 | N/A | N/A | N/A | |
 Clene Inc. NASDAQ:CLNN | -2.65 | N/A | N/A | N/A | |
 Immix Biopharma, Inc. NASDAQ:IMMX | -0.89 | N/A | N/A | N/A | |
 Zentalis Pharmaceuticals, Inc. NASDAQ:ZNTL | -1.91 | N/A | N/A | N/A | |
 aTyr Pharma, Inc. NASDAQ:ATYR | -0.80 | N/A | N/A | N/A | |
 Biomea Fusion, Inc. NASDAQ:BMEA | -1.18 | N/A | N/A | N/A | |
 eXoZymes, Inc. NASDAQ:EXOZ | -1.09 | N/A | N/A | N/A | |
 Fractyl Health, Inc. Common Stock NASDAQ:GUTS | -1.86 | N/A | N/A | N/A | |
 Oramed Pharmaceuticals Inc. NASDAQ:ORMP | 1.53 | 121.9% | N/A | N/A | |
 Quince Therapeutics, Inc. NASDAQ:QNCX | -1.31 | N/A | N/A | N/A | |
 Spruce Biosciences, Inc. NASDAQ:SPRB | -50.83 | N/A | N/A | N/A |
Anebulo Pharmaceuticals, Inc. Fair Value Envelope
Related Guides
Continue your ANEB research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.